FDA committee votes to pull boxed warning from Chantix
Pfizer has moved a giant leap closer to getting the strongest warning of serious neuropsychiatric events removed from the labelling of its anti-smoking drug Chantix in the US.
Read More
Tag: Chantix
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
